CSL Announces Half Year Results

ZLB Bioplasma contributes strongly to CSL's record profit growth

Melbourne, Australia — 20/02/2001

CSL Limited today announced an operating profit after tax (before amortisation of goodwill) of $37.3 million for the six months ended 31 December, 2000, an increase of 100.5% on the previous corresponding half year's result. Group sales totalled $335.4 million, an increase of 60% over the corresponding period last year with international sales now accounting for 52% of Group revenues.

Earnings per share (diluted) before amortisation also increased to 24.5 cents, an increase over the corresponding period last year of 77%.

Dr McNamee, CSL's Managing Director, said that he was very pleased with this result due to the continuing performance of CSL's core activities and the initial strong sales performance from ZLB Bioplasma AG which had effectively commenced operations from 1 September, 2000.

Dr McNamee also indicated that he was delighted with the progress being made on integrating the operations of ZLB into the CSL Group.

The Directors declared an interim dividend of 9 cents per share fully franked to be paid to shareholders on 25 April, 2001. This compares to an interim dividend of 8 cents per share for the same period last year.

For further information contact:

Dr Brian McNamee
Managing Director
Ph: (03) 9389 1376

Mr Tony Cipa
Finance Director
Ph: (03) 9389 1319

Group Results December2000 $m1999 $m
Other Revenue8.14.6
Total Revenue343.5214.1
Net Interest Expense6.0(1.0)
Tax Expense10.88.9
Profit after tax before amortisation37.318.6
Net Profit27.318.6
Interim Dividend (cents)9.08.0
EPS (cents)18.314.1
EPS after tax before amortisation (diluted)24.514.1
© 2017 CSL Limited